Document Detail


Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients.
MedLine Citation:
PMID:  17119331     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: CC-chemokines are now widely accepted in the recruitment of leukocytes from the blood compartment into tissues, and their role in the progression of atherosclerosis has been documented. Recombinant human erythropoietin (EPO) has become widely used to treat anemic HD patients. However, little is known about the effect of EPO on the plasma CC-chemokine levels and intima-media thickness (IMT) in HD patients. METHODS: Assessment of CC-chemokines: monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory proteins (MIP-1alpha, MIP-1beta), regulated upon activation, normal T cell expressed and secreted (RANTES) and IMT were performed in 26 stable HD patients and 15 healthy controls. The patients were divided into 3 groups: group I (n = 8, without EPO), group II (n = 9, EPO at a mean dose of 76 +/- 48 U/kg/week for more than 4 months), and group III (n = 9, EPO at a mean dose of 110.5 +/- 21 U/kg/week for more than 12 months), none of them on iron therapy. RESULTS: MCP-1, MIP-1alpha, MIP-1beta and IMT values were significantly higher, whereas RANTES were significantly lower in HD patients without EPO therapy than those in healthy controls. CC-chemokine levels were found to be significantly lower in patients administered EPO when compared to subjects without EPO. In the patients treated with EPO for more than 12 months IMT values were significantly decreased compared to patients not receiving this hormone. CONCLUSION: These results suggest that long-term EPO therapy decreased CC-chemokine and IMT values in patients undergoing regular HD in the absence of concomitant iron supplementation.
Authors:
Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Publication Detail:
Type:  Journal Article     Date:  2006-11-21
Journal Detail:
Title:  American journal of nephrology     Volume:  26     ISSN:  0250-8095     ISO Abbreviation:  Am. J. Nephrol.     Publication Date:  2006  
Date Detail:
Created Date:  2006-12-28     Completed Date:  2007-02-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8109361     Medline TA:  Am J Nephrol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  497-502     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2006 S. Karger AG, Basel.
Affiliation:
Department of Nephrology and Clinical Transplantation, Medical University, Bialystok, Poland. krystynapawlak@poczta.onet.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Atherosclerosis / pathology,  prevention & control
Carotid Arteries / drug effects*,  pathology
Chemokines, CC / antagonists & inhibitors*,  blood*
Erythropoietin / therapeutic use*
Female
Humans
Male
Middle Aged
Renal Dialysis*
Tunica Intima / drug effects*,  pathology
Tunica Media / drug effects*,  pathology
Uremia / blood*,  drug therapy,  pathology*,  therapy
Chemical
Reg. No./Substance:
0/Chemokines, CC; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pseudo-Pelger-Huët in kidney-transplanted patients.
Next Document:  Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-elemen...